• Explore /
  • Poster
  • / Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).

Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).

Abstract Poster

Authors

null

Qiu-Yan Chen

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Guangzhou, China

Qiu-Yan Chen , Hai-Qiang Mai , Dong-Ping Chen , Chao-su Hu , Kunyu Yang , Jiyu Wen , Jingao Li , Yingrui Shi , Feng Jin , Ruilian Xu , Jian-ji Pan , Shenhong Qu , Ping Li , Chunhong Hu , Yi-Chun Liu , Yi Jiang , Xia He , Hung-Ming Wang , Darren Wan-Teck Lim , Rui-Hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03581786

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 6039)

DOI

10.1200/JCO.2024.42.16_suppl.6039

Abstract #

6039

Poster Bd #

342

Abstract Disclosures

Similar Posters

First Author: Hai-Qiang Mai

First Author: Majd Issa

First Author: Theresa Bayt

First Author: Huiyan Luo